Stress-induced cardiomyopathy due to chronic psycho-emotional overstrain: A separate nosologic entity or a debut of the ischemic heart disease?

Resume
Stress-induced cardiomyopathy due to chronic phsycho-emotional overstrain we call non-ischemic disturbances of repolarisation on ECG or/and cardiac arrhythmias in patients with chronic phsyco-emotional overstrain. The results of the investigation of the main indicators of cholesterol metabolism (such as: total cholesterol, LDL/HDL ratio, LDL, triglycerides) and several genetic markers associated with the early development of atherosclerosis (MTHFR gene, ApoE gene) in engine-drivers with stress-induced cardiomyopathy are presented. Patients with stress-induced cardiomyopathy show more frequent availability of T-allele of MTHFR gene compared with healthy male population of St-Petersburg. Increase of the total cholesterol level and LDL/HDL ratio in patients with the signs of stress-induced cardiomyopathy was found. Our data demonstrate the association between ApoE*4 allele with increased levels of total cholesterol and LDL fraction of blood serum, and the association between ApoE*2 allele with increased level of triglycerides as well.
Results: therefore, lipid metabolism disturbances and C677T polymorphism MTHFR gene might take part in developing stress-induced cardiomyopathy. So E*2/E*3/E*4 polymorphism ApoE gene might take part in atherosclerotic leasuned in persons subjected to chronic stress.

stress-induced cardiomyopathy , engine-driver , cholesterol , low-density lipoproteins , methylentetrahydrofolate reductase gene , apolipoprotein E gene

1. Rozsival V. Is the negative T-wave on the ECG always a sign of ischemia? (human stress cardiomyopathy?) Vnitr Lek. 2002 Dec.48 Suppl 1:210-2.

2.

3. Lee S.Y., Lee C.Y., Kim H.J., Lee H.H. et al. Stress-induced cardiomyopathy presenting as acute myocardial infarction. Yonsei Med J. 2002 Oct; 43(5):670-4

4.

5. Fazio G., Barbara G., Loredana S. et al. Clinical findings of Takotsubo cardiomyopathy: results from a multicenter international study. Journal of Cardiovascular Medicine. 2008 March 9(3):239-244.

6.

7. Coumel P., Fidelle J.,Lucet V. et al. Catecholaminergic-induced severe ventricular arrhythmias with Adams-Stokes syndrome in children. BrHeart J 1978;40:28-37

8.

9. Leenhardt A., Lucet V., Denjoy I., et al Catecholaminergic polymorphic ventricular ventricular tachycardia in children. A 7-year follow-up of 21 patients. Circulation 1995;91:1512-9

10.

11. Davis A.M., Natelson B.Li. Brain-Heart Interactions. The neurocardiology of arrhythmia and sudden cardiac death. Tex. Heart Inst. J. 20: 158-169, 1993

12.

13. Rubart M., Zipes P.D. Mechanisms of sudden cardiac death. J. clin. Invest. 2005.115:2305-2315.

14.

15. Ланг Г.Ф. О поражениях сердечной мышцы и об электрокардиографических проявлениях с биохимической точки зрения. В кн.:Вопросы патологии кровообращения и клиники сердечно-сосудистых болезней. - Л.: Биомедгиз. - 1936. - Вып. I. - с. 77-137.

16.

17. Дембо А.Г. О синдроме перенапряжения левого желудочка у здоровых людей. Кардиология.-1962.-№3.-С70-78

18.

19. Гаврилова Е.А. Спортивное сердце. Стрессорная карди-омионатия. - М.: Советский спорт.- 2007.- 200 с.

20.

21. Хомуло П.С. Эмоциональное напряжение и атеросклероз. Л.Медицина, 1982.-232с.

22.

23. Ghiadoni L., Donald A.E., Cropley М., et al. MentalStress Induces Transient Endothelial Dysfunction in Humans.Circulation. 2000:102:2473.

24.

25. Roy M.P., Kirschbaum C., Carmena R. et al. LP(a) levels and atherosclerotic vascular disease in sample of patient with familial hypercholesterolemia sharing the same gene defect. Atheroscler. Thromb.Vasc.Biol <http://Thromb.Vasc.Biol>. -2001-V.16.-P.129-126

26.

27. Лопухин Ю.М., Арчаков A.M., Владимиров Ю.А., Коган Э.М. Холестериноз (холестерин мембран, теоретические и клинические аспекты). М.: Мед. - 1983. - 318 с.

28.

29. Гаврилова Е.А. Стрессорная кардиомиопатия у спортсменов (дисторофия миокарда физического перенапряжения). - дисс.Д.М.Н. -СПб.-2001. -337с.

30.

31. Климов А.Н., Перова Н.В., Трюфанов В.Ф. и др. Липи-ды и липопротеиды плазмы крови в популяциях мужчин и женщин в возрастном аспекте. Эпидемиология и факторы риска ишемической болезни сердца. Под ред. А.Н. Климова.-Л., 1989.-С.36-57.

32.

33. Seidman J., Morita Н., Seidman Ch. Genetic causes of human heart failure. J. Clin. Invest., Mar 2005; 115: 518-526.

34.

35. Cattaneo M., Tsai M.Y., Bucciarelli P et. al. A commonmutation in the methylenetetrahydrrofolate reductase gene(C677T) increases the risk for deep-vein thrombosis in patientwith mutant factor V. Atherosc.Thromb.Vase. Biol. 1997:17:1662-1666

36.

37. Мухин Н.А., Моисеев С.В., Фомин В.В. Гипрегомоцистеи-немия как фактор развития заболеваний сердечно-сосудистойсистемы. Клин. мед. 2001;6:7-14

38.

39. Wilcken D.E., Wang X.L., McCredie R.M. Genotypedistribution of angiotensin-converting enzyme polymorphism inAustralian healthy and coronary populations and relevance tomyocardial infarction and coronary artery disease. ArteriosclerThromb Vasс Biol 1996; 16(1): 115-119.

40.

41. Hennekens Ch. H. Increasing Burden of CardiovascularDisease Circulation. 1998; 97:1095-1102.

42.

43. Ларионова В.И. Клинико-генетический анализпредрасположенности к развитию атеросклероза у детей иподростков. Дисс.д.м.н. СПб.-2005.-205с.

44.

45. Хавинсон В.Х., Соловьева Д.В., Стрекалов Д.Л. и др. Анализ распределения в российской популяции некоторых генетических маркеров, ассоциированных с мультифактори-альной патологией среднего и пожилого возраста. Мед. акад. журн. - 2002.-2,4.-56-66.

46.

47. Pitsavos С., Panagiotakos D., Chrisohoou С. et al. Coronary risk in people with increased oxidative stress. Nutr. Metab. Cardiovasc Dis.Germany2006 Mar;16(2):91-9

48.

49. Agerholm-Larsen В., Nordestgaard B. G., Tybjrg-Hansen A.ACE gene polymorphism in cardiovascular disease. Meta-analyses of small and large studies in whites. Arterioscler Thromb VaseBiol.-2000.-V <http://Biol.-2000.-V>. 20.-P.484-492.

50.

51. Mansur A.P., Annicchino-Bizzacchi J., Favarato D., et al. Angiotensin-converting enzyme and apolipoprotein В polymorphisms in coronary artery disease. Am J Cardiol 2000; 85: 1089-1093.

52.

53. Samani N.J., Thompson J.R., O'Toole L. et al. A metaanalysis of the association of the deletion allele of the angiotensin-converting enzyme gene with myocardial infarction. Circulation 1996; 94; PP. 708-712.

54.

55. Fatini C., Abbate R., Pepe G. et al. Searching for a better assessment of the individual coronary risk profile; the role of angiotensin-converting enzyme, angiotensin II type 1 receptor and angiotensinogen gene polymorphisms. Eur Heart J 2000;21:633-638.

56.

57. Mahley R.W. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1999; 240:622-30

58.

59. Knouff Ch., Hinsdale M. E., Mezdour H. et al. Apo E structure determines VLDL clearance and atherosclerosis risk in mice. J Clin Invest, June 1999, Volume 103, Number 11, 1579-1586

60.

61. Zechner R., Kratky D., Zimmermann R., et al. Endothelial lipase provides an alternative pathway for FFA uptake in lipoprotein lipase-deficient mouse adipose tissue. J. Clin. Invest., Jan 1997; 115:161-167.

62.

63. Strike P.C., Steptoe A. Depression, stress, and the heart. Heart 2002; 88:441-443

64.

65. Welch G., Loscalzo J. Homocysteine and atherothrombosis. N. Engl J Med 1998; 338(15):1042-1050

66.

67. Kuusi Т., Nieminen M.S., Ehnholm C. et al. Apoprotein-E polymorphism & coronary artery disease. Increased prevalence of apolipoprotein E-4 in angiographically verified coronary patients. Arteriosclerosis,- 1989.-V.9.-P.237-241.

68.

69. Wilson P. W., Schaefer E.J., Larson M.G. et al. Apolipoprotein E alleles and risk of coronary disease. A meta-analysis. Arterioscler Thromb Vase Biol 1996;16:1250-55

70.

71. Eichner J.E., Kuller L.H. et al. Relation of apolipopritein E phenotype to myocardial infarction and mortality from coronary artery disease. Am. J. Cardiol. - 1993- V.71 N 2.- P.160-165.

72.

73. Stengard J.H., Zerba K.E., Pekkanen J., et al. Apolipoprotein E polymorphism predicts death from coronary heart disease in a longitudinal study of elderly Finnish men. Circulation 1995;91:265-9

74.

75. Hagberg J.M., Wilund K.R., Ferrell R.E. APO E gene and gene-environment effects on plasma lipoprotein-lipid levels. Physiol Genomics 2000; 4:101-108.

76.

77. Gerdes L.U., Gerdes C., Kervinen K. et al. The apolipoprotein 4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction. Circulation 2000; 101(12): 1366-1380.

78.

79. Van Bockxmeer F.M., Mamotte C.D. Apolipoprotein epsilon 4 homozygosity in young men with coronary heart disease. Lancet. -1992.-V.340.-P.879-880.

80.

81. Havel R.J. The formation of LDL : mechanisms and regulation. J. Lipid Res.-1984.-V.25.-P.1570-1576.

82.

83. Hixon J.E. Apolipoprotein E polymorphism affect atherosclerosis in young males. Arterioscler Thromb.-199 l.-V.ll.-P.1237-1244.

84.

85. Orth M., Weng W., Funke H. et al. Effects of a frequent apolipoprotein isoform? Apo E4Freiburg (Leu28→Pro), on lipoproteins and the prevalence of coronary artery disease in whites. Arterioscler Thromb Vascul Biol 1999; 19 (5): 1306-1315.

86.